debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC

There's lots of debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC.

The FDA is holding meetings...and considering it for the U.S. Canadian officials are watching this closely.

Several medical and pharmacy associations strongly support it.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote